And Pharmacyclics.

Like Abbott’s additional collaborations in the region of companion diagnostics, our goal is certainly to leverage molecular technologies to help ensure that the right medicine gets to the right person, said John Coulter, vice president, Molecular Diagnostics, Abbott. Cancer is a complicated disease where, historically, therapies have demonstrated just a 25 % efficacy rate. Companion diagnostic tests can help improve these outcomes by choosing patients that will respond to specific therapies, reducing time to the very best treatment and increasing the number of positive outcomes. According to the American Society of Clinical Oncology , future malignancy therapies will be developed through molecular approaches that may accelerate development of far better, personalized treatments.. The study found most believe home healthcare technology gets the potential to relieve pressure on healthcare systems that will shortly be clogged by elderly individuals living with chronic diseases. However the evidence continues to be not strong enough showing the gadgets are cost-effective and ready for widespread adoption . This content was reprinted from with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an independent news service editorially, is an application of the Kaiser Family Foundation, a nonpartisan healthcare policy research company unaffiliated with Kaiser Permanente.

2010 promises to keep acquisition activity as companies seek ways to bolster their pipelines and portfolios According to pharmaceutical offer makers, the recent circular of sector M&A is far from over.